Dyadic International, Inc. announced it has received a funding award from the Coalition for Epidemic Preparedness Innovations (CEPI). This award is specifically for utilizing the company's C1 platform to accelerate the development of protein-based vaccines.
The funding supports Dyadic's efforts to advance its biopharmaceutical capabilities through collaborations with globally recognized organizations. The company is eligible for up to $2.4 million from a larger $4.5 million CEPI grant.
This initiative is expected to contribute to the development of biopharmaceutical pipelines and create additional growth opportunities in both human and animal health markets. The C1 platform is recognized for its potential in efficient, large-scale protein manufacturing for vaccines.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.